SEC Form 4 · accession 0001178913-18-003085
Foamix Pharmaceuticals Ltd. · FOMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew T. Wiley
Officer — Chief Commercial Officer
Period of report
Dec 3, 2018
Accepted (ET)
Dec 4, 2018 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001606645
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2,F3 | Dec 3, 2018 | A | 50,000 | $0.00 | A | 50,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OptionsF4,F1,F5 | $4.06 | Dec 3, 2018 | A | 100,000 | A | — | Dec 3, 2028 | Ordinary Shares | 100,000 | 100,000 | D |
Explanation of responses
- F1The equity incentive grants were approved by the Issuer's board of directors on the recommendation of a committee of the board on November 14, 2018 with a grant date of December 3, 2018.
- F2The ordinary shares underlying this restricted share unit award vest over a period of four years from the end of the calendar quarter in which the grant was made (25% on December 31, 2019 and 6.25% every three months thereafter) ending December 31, 2022.
- F3This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer.
- F4Each option represents a contingent right to purchase one ordinary share of the issuer.
- F5The ordinary shares underlying these options vest over a period of four years from the end of the calendar quarter in which the grant was made (25% on December 31, 2019 and 6.25% every three months thereafter) ending December 31, 2022.